Float, hi.
A quick re read of the May investor presentation, I’m sure, will refresh your knowledge. CelGro’s primary target markets are 1) Bone regeneration 2) Tendon and soft tissue and 3) peripheral nerve regeneration. These test outcomes refer to peripheral nerve regeneration. I’m afraid if you thought this stock was about injuries to the spine, you are completely mistaken. Where you maybe getting confused is in believing that a quadriplegic cannot recover some of their feelings or movement in any of their limbs.
Anyway, these results are most welcome and provide further evidence that OCC are well advanced in their field. At $60 mill market cap and $10 mill in the bank, with these results, this is a steal below 50c.
Float, hi. A quick re read of the May investor presentation, I’m...
-
- There are more pages in this discussion • 208 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $76.49M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.5¢ | $33.04K | 89.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 54459 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 14827 | 1 |
View Market Depth
| Last trade - 15.46pm 14/08/2024 (20 minute delay) ? |
| OCC (ASX) Chart |